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Biofabrication of tissue analogues is aspiring to become a disruptive technology cap-
able to solve standing biomedical problems, from generation of improved tissue
models for drug testing to alleviation of the shortage of organs for transplantation.
Arguably, the most powerful tool of this revolution is bioprinting, understood as the
assembling of cells with biomaterials in three-dimensional structures. It is less appre-
ciated, however, that bioprinting is not a uniform methodology, but comprises a
variety of approaches. These can be broadly classified in two categories, based on
the use or not of supporting biomaterials (known as “scaffolds,” usually printable
hydrogels also called “bioinks”). Importantly, several limitations of scaffold-depen-
dent bioprinting can be avoided by the “scaffold-free” methods. In this overview,
we comparatively present these approaches and highlight the rapidly evolving scaf-
fold-free bioprinting, as applied to cardiovascular tissue engineering.
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1 | INTRODUCTION
There are several reasons to dedicate a special discussion to biofab-
rication and bioprinting for cardiovascular medicine. One is the
intrinsic importance of the cardiovascular disorders, still the leading
cause of mortality in United States and worldwide. One in three per-
sons who recently died was of a cardiovascular disease in the United
States only, and in other countries, the death toll was even higher.1
For this reason, some of the largest research efforts (and funding
resources) have been traditionally put into this area. Moreover, the
cardiovascular surgeons have been pioneering the direct tissue
replacement by organ transplantation: this year is the 50th anniver-
sary of the first heart transplantation by Christin Barnard in South
Africa. Other approaches besides the pharmacological interventions
aiming at structural repair and functional recovery are vascular graft-
ing2 and the direct cell therapy. Therefore, it is no surprise that car-
diovascular tissue engineering and, in particular, 3D printing and
bioprinting are major areas of current interest and advances in car-
diovascular medicine3.
Another reason of the importance bioprinting has for vascular
biology is the universal need for vascularization of any tissue
engineered construct larger than about half millimetre, as 200 lm
is the limit of free oxygen diffusion in living tissues. Combined
with the difficulty to provide an innervation, the lack of microvas-
cular perfusion is a major roadblock to scaling-up of many
promising functional proofs of concept in biofabrication of live
tissues.4
Here, we will leave out multiple applications of 3D printing (with
no cells involved) to cardiovascular field, as well as the scaffold-only
printing,5 and the “hybrid” forms of bioprinting,6 which have been
discussed in other excellent reviews recently.3 Instead, we will high-
light scaffold-free bioprinting as bona fide biofabrication, here under-
stood as the creation of living, functional 3D constructs with
cardiovascular applications.
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2 | BIOINK-BASED BIOPRINTING AND ITS
LIMITATIONS
As directly derived from 3D printing,7,8 and thus inheriting much of
the ongoing technological progress in additive manufacturing, one of
the major advantages of the scaffold-dependent bioprinting is the
easiness to design and implement the construct’s configuration, by
direct image input via computer-assisted design (CAD) files.3,7
Another favourable feature, making it preferable for large, cell-homo-
genous, matrix-rich tissues such as bone, cartilage, muscle, is its
excellent scalability.9 However, although new biological bioinks are
emerging, for example, collagen- or fibrin-based,10,11 the structural
cohesion (the “glue”) is obtained by still non-universal, sometimes
proprietary and/or expensive polymeric materials in form of hydro-
gels.12 As these hydrogels are essentially soft materials, in order to
provide the constructs with the necessary biomechanical properties,
they require a hardening step, usually a chemically- or UV-induced
polymerization.13 This can be cell-damaging and thus significantly
reduce the efficiency of the process. As an alternative is the “hybrid”
bioprinting, consisting of incorporation in the construct of a second,
usually fibrillary biomaterial.6
Cell loss may occur during material-dependent bioprinting for a
variety of method-specific reasons. For example, during droplet gen-
eration substantial energy is delivered to the sample leading to vibra-
tion, heating and/or strong electrical fields.12 Milder bioprinting
methods are currently developed, such as the laser-assisted bioprint-
ing.14 In this method, a laser pulse locally melts a “bioribbon” that
consists of a cell-embedding gel, thus generating a droplet deposited
with high precision according to the desired 3D pattern. Still, cell
viability could be an issue even with this method.15
Cells “encapsulation” within the supporting gel may additionally
impair intercellular communication, although for several matrix-rich
tissue types such as bone and cartilage, this might be lesser of a
problem. If the cells survive the initial isolation, this may be reduced
in time with the slow diffusion of paracrine factors through the por-
ous material and/or dissolution of the embedding matrix, followed
by reducing of intercellular distances by proliferation and relocation.
As opposed to the surface which can be highly anatomically real-
istic, when examining the internal cellular architecture of most 3D
constructs bioprinted so far,16,17 their spatial organization is quite
simplistic, following easily accessible geometric patterns rather than
tissue structure, as tissues incorporate a larger amount of random-
ness and/or more structural refinement, such as fractal spatial distri-
butions. 3D printing itself could be made - in theory at least, given
its high resolution - more naturalistic; thus, this limitation might be
considered to originate at the structural design stage. In some cases,
after their initial deployment, the cells relocate within the bioprinted
object, or following the biomaterial dissolution, allowing more natural
cell arrangements.
Another essential issue facing biomaterial-based bioprinting
strategies is their biocompatibility. On the one hand, the energy-
intensive droplet producing processes may generate secondary
molecular products from the gels, which could be directly cytotoxic
either for the embedded cells,18 or for the recipient organism after
construct’s implantation. In addition, these biomaterials may trigger
foreign-body reactions to the implant.7 These will be likely less seri-
ous in the future when more “biological” bioinks will be used. Even
so, both collagen and fibrin are reminiscent of wound-healing and
pro-inflammatory processes, which might signal to the embedded
cells subtle corresponding responses.
At the interface between scaffold-dependent and scaffold-free
bioprinting lies the use of “bioinks” prepared exclusively from natural
materials, such as collagen or fibrin, or even organ-specific extracel-
lular matrices.19 Although still experiencing some of the limitations
of their deployment methods, the latter option is the most promising
in terms of biocompatibility and capable of mitigating other down-
sides of the “bioinks” discussed above.
3 | BIOMATERIAL-INDEPENDENT
(“SCAFFOLD-FREE” ) BIOPRINTING
Many of the problems related to the biomaterial use in bioprinting
could be eliminated if only cells were used instead.20 One such prob-
lem is related to biocompatibility, which can be much increased,
especially if patient-derived cells are used (e.g., adult mesenchymal
stem cells, or induced pluripotent stem cells, iPSC;21), possibly lead-
ing to creation of fully autologous constructs.22
Several such methods have been developed in the last couple of
years, each with their advantages and disadvantages. A common lim-
itation of this approach is that although cells can be manipulated
individually, they do not easily form stable assemblies by simply
bringing and maintaining them in contact, unless the intercellular
adhesions are made very strong, possibly by chemical means.23 Addi-
tional structural cohesion needs to be produced by the cells, as their
own secreted extracellular matrix. However, this may take longer
time and depends on cell type and quality of matrix deposition. For
this reason, the cells are first pre-assembled in clusters (most often
“spheroids”) and tested for the ability to secrete the “glue” needed
to further combine them in larger-scale constructs.20 Even so, the
biomechanical properties of the constructs are less predictable than
when using a pre-defined material. If this matrix is insufficient or
inappropriate for the contemplated applications, “hybrid” spheroids
can be created, by adding supplementary matrix.24
The spheroid-based methods are in general gentler and thus
induce much less or no cell damage during the procedures. Another
attractive feature of scaffold-free bioprinting is its efficiency, as the
speed can be comparable or even higher than other forms of bio-
printing by using as “building blocks” large spheroids (in the tens of
thousands cells25).
Although the scaffold-free cell assembling methods do not have
the common problems of inkjet and micro-extrusion (such as the
nozzle clogging), they still have their own technical limitations. One
is the time of pre-printing preparations which tend to be longer,
while the post-printing maturation time is probably comparable
between the two approaches. Moreover, in such constructs, the
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cellular cross-talk proceeds naturally, while optional addition of
hydrogels in between the cells and within spheroids still remains
possible and probably beneficial.26,27 Thus, since scalability is more
limited, scaffold-free-methods are preferable for smaller, cell-hetero-
geneous, matrix-poor tissues where the immediate (or continuous)
intercellular communication is important.
A defining property of this biofabrication approach is that the tis-
sue structure does not strictly follow a pre-determined design, but
emerges from fundamental developmental principles, more similar to
embryological or organoid biology.28 The “voxel” of this form of bio-
printing being the spheroid, a consequence is that the relative reso-
lution is in the range of hundreds of microns. In practice, the
positioning of cells can be known with much more precision because
they attain predictable locations within the spheroids.29 Alterna-
tively, more precision of cell location may not be needed, or could
even be detrimental if it prevented the unfolding of self-organization
mechanisms during the so-called post-printing maturation phase.
Another implication of the basically biophysical nature of the fac-
tors at work during scaffold-free biofabrication bears on the types of
possible applications, as well as the required training, competencies
and mindset of the users and of this technology’s operators. Never-
theless, as a branch of bioengineering the scaffold-free biofabrication
remains a quantitative discipline, with the potential to benefit from
advanced analytics and biosensors, molecular-level optimization and
computer modelling.30-32
4 | HYDROGELS AS TEMPORARY
SCAFFOLDS
Steps towards cells-only bioprinting were previously attained by using
“sacrificial” or “fugitive” hydrogels. For example, one of the best-
known bioprinting company in United States is Organovo, which
launched the bioprinter NovoGen. On this machine, pre-formed cylin-
drical cell aggregates are placed in between alginate rods of similar
diameters in pre-defined geometry and held in place until the cellular
structures fuse in a continuous cellular mass. Then, the hydrogel is dis-
solved, leaving behind a “scaffold-free” construct. By this approach,
vascular,33 nerve,34 liver35 and kidney36 structures were demonstrated
and now commercialized for in vitro pharmacological assays.
Another technology is that of the company 3D Bioprinting Solu-
tions, which similarly employs “fugitive” hydrogels for holding in
place cells spheroids for fusion in larger-scale structures - in this
case, thyroid glands, currently being tested in athymic mice.37 Simi-
larly, this approach of high-density cell cords was adapted to bio-
printing of vascular tubes from cells compacted in alginate tubes and
then re-loaded after supporting hydrogel removal in an extrusion
bioprinter for 3D assembling.38 In all these cases, at least at one
point in the process the cells are placed in contact with the biomate-
rial, with all the implications discussed before.
Cell-sheet technology, depending on a detachable polymeric sub-
strate for cellular sheet lifting, can also be used to create more
sophisticated 3D structures.39
5 | RECENT DEVELOPMENTS IN
CARDIOVASCULAR SCAFFOLD-FREE 3D
BIOPRINTING
A variety of hydrogel-free methods to make 3D tissue analogues
also exist. For space limitations, we’ll address only two versions,
magnetic and mechanical (microneedles) methods.
5.1 | Magnetic assembling of model cardiovascular
tissues
In theory at least, the cells can be brought together in 3D structures
and maintained in position for long enough to interact and reconsti-
tute their native environment, using the magnetic force. Magnetic
micro- and nano-beads are creatively and intensively explored for a
variety of applications following this paradigm.
In one of its embodiments, the magnetic method speeds up the
formation of spheroids and then their assembling into larger con-
structs. Two groups are particularly active in this area and thus
deserve special attention. One is the company Nano3D, which com-
mercializes a kit allowing the labelling of cells with nano-particles
and the magnet to pull them down (“bioprint”) or up (“levitate”).40
The beads bind the cell surface non-specifically (via electrostatic
forces) and reversibly, as they are eventually either released in the
medium or internalized to some extent (without detectable side-
effects on the cells). Therefore, the method is said to be universal
regarding the phenotype of the involved cells, although the stability
of the spheroids and thus of the resulting constructs may vary. Using
this regent, a series of high-profile papers have been published, with
examples in vascular,41,42 pulmonary43 and tumour,44,45 biology.
Other similar magnetic beads-based methods are pursued in aca-
demic environments. Relevant to this discussion are the Janus’-like
microbeads which are internalized46 and were demonstrated to assist
the formation of vascular-relevant structures.47-49 While these meth-
ods are definitely useful for in vitro models and experimentation,
their translation to clinical practice is more questionable, particularly
due to the limited size of the constructs and the residual magnetic
material.
5.2 | The microneedles-based “Kenzan” bioprinting
A radical alternative to hydrogels for providing a temporary support
to spheroids, and thus facilitating their fusion and maturation in
meaningful tissue models, is the use of a set of microneedles (“Ken-
zan” in Japanese).50 This method is implemented in the Regenova
“Bio-3D Printer” commercialized by Cyfuse Biomedical K.K. and in
United States by its subsidiary Amuza, Inc. (Figure 1A). Currently,
there are several such instruments operational in Japan and a few in
the United States (to our knowledge, two in academic and one in a
corporate institution). For a comprehensive discussion of this tech-
nology, we suggest our recent review.25
Several functional tissue constructs have been assembled so far
on the Regenova robot. Among them is a small-diameter (inner
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diameter of 1.5 mm and 7 mm in length) vascular graft tested
in vivo.51 To this end, human cell spheroids were prepared from
2.5 9 104 cells/spheroid of 40% umbilical vein endothelial cells (EC),
10% aortic smooth muscle cells and 50% dermal fibroblasts (FB) and
maintained in a cocktail of corresponding growth media in the pro-
portion 1:1:1. These spheroids were printed as tubular constructs in
the microneedles following a pre-designed pattern (Figure 1B) and
maintained for fusion for 4 days. Then, the tubes were removed
(Figure 1C) and perfused for an additional 7 days. The tubes were
surgically implanted and sutured into the abdominal aortas of nude
rats. Blood flow was assessed the by ultrasonography, and all grafts
were found to be patent for the 5 days of the experiment. This was
terminated due to significant enlargement and thinning of the grafts.
At immuno-histological examination, EC were found redistributed to
an intimal layer, probably explaining the patency of these grafts.
Using the same technology, tracheal52 and uretral53 tubes were
obtained, as well as neural bridges54 and liver buds.55 Yet probably
the most notable accomplishment to date is the bioprinting of a
functional cardiac patch56 (Figure 2). The spheroids were prepared
from human induced pluripotent stem cell-derived cardiomyocytes
(CM), FB and EC, in the proportions CM:FB:EC = 70:15:15, 70:0:30
or 45:40:15. These were assembled using the Regenova bioprinter.
After bioprinting, these cardiac tissue patches of all cell ratios not
only beat spontaneously, but also exhibited ventricular-like action
potential waveforms and uniform electrical conduction. Reproducing
a feature of cardiac fibrosis, the conduction velocities were higher
and action potential durations were longer in patches containing a
lower percentage of FB. CM, FB and EC markers were detected by
immunohistochemistry both in spheroids and in the formatted tissue
patches. EC displayed signs of self-assembling towards capillary
F IGURE 2 Schematic of biomaterial-free bioprinting of a cardiac patch. A, Cells (CM, FB, EC) are aggregated in ultra-low attachment 96-
well plates to form spheroids. B, The desired 3D structure is designed using computer software. C, The robot picks up individual spheroids
using vacuum suction and loads them onto a needle array. D, Spheroids are allowed to fuse. The 3D bioprinted cardiac tissue is then removed
from the needle array and further cultured to allow the needle holes to be resorbed (reproduced with permission from Ong et al56)
A CB
F IGURE 1 Scaffold-free bioprinting of a vascular graft on the Regenova bioprinter. A, Frontal view of the robot, together with its
controlling computer. B, Virtual design of the spheroids positioning in the tube. C, Actual construct demonstrating surgical robustness for
implantation (modified with permission from Itoh et al51)
MOLDOVAN | 2967
primordia. After implantation on the surface of the myocardium in
immune-deficient rats, these pre-vascular structures became per-
fused with recipient blood, indicating spontaneous anastomosis.
In conclusion, cardiovascular tissue engineering benefits from
recent technological progress, in particular from bioprinting, which
comes in two complementary flavours, as dependent or not on a
bioink. Collectively, both these approaches hold the potential to
transform the way cardiovascular diseases are treated in the future
(see Table 1 for a summary comparison of scaffold-dependent and
independent methods).
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